"Virginia Cancer Specialists offers a dedicate team of medical oncologists, hematologists, oncology nurses, oncology pharmacists and a research department, all working on your behalf to provide comprehsensive, advanced cancer care in your community."

During the past decade, Virginia Cancer Specialists-Fairfax conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Virginia Cancer Specialists-Fairfax" #1 sponsor was "Ariad Pharmaceuticals" with 2 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Aminex Therapeutics, Inc." with 1 trials sponsored, "Arcus Biosciences, Inc." with 1 trials sponsored and "Cardiff Oncology" with 1 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Virginia Cancer Specialists-Fairfax" #1 collaborator was "National Cancer Institute (NCI)" with 2 trials as a collaborator, "Gilead Sciences" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Takeda" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Virginia Cancer Specialists-Fairfax" are "ALK-positive Advanced NSCLC" (1 trials), "Acute Myeloid Leukemia" (1 trials), "Advanced Cancer" (1 trials), "Advanced Malignancies" (1 trials) and "Advanced Solid Tumor" (1 trials). Many other conditions were trialed in "Virginia Cancer Specialists-Fairfax" in a lesser frequency.

Most popular intervention types in "Virginia Cancer Specialists-Fairfax" are "Drug" (14 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Brigatinib" (2 trials), "Cyclophosphamide" (2 trials), "Nivolumab" (2 trials), "Paclitaxel" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Virginia Cancer Specialists-Fairfax" are 13 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Virginia Cancer Specialists-Fairfax". undefined are not yet recruiting, 5 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Virginia Cancer Specialists-Fairfax, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Virginia Cancer Specialists-Fairfax, 7 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Virginia Cancer Specialists-Fairfax has several departments that took part in Clinical trials: "Virginia Cancer Specialists" - 5 trials, "Virginia Cancer Specialists, PC" - 4 trials, "NEXT Oncology - Virginia Cancer Specialists" - 6 trials